Kornimate/medical-research-clean huggingface dataset:
electroencephalographic changes under general anesthesia in patients with gynecologic cancers with and without history of chemotherapy

Conditions: Malignant Female Reproductive System Neoplasm

Summary: this study compares changes in brain waves in women with gynecologic cancers who have or have not received chemotherapy and who are scheduled to receive surgery as part of their standard care. electroencephalography is a test that measures brain waves and may help learn if sensitivity to anesthesia is higher in women who have received chemotherapy than women who have not. this study may help researchers learn if receiving chemotherapy before surgery can affect the way the brain responds to anesthesia during and after surgery.

primary objective: i. to assess electroencephalography (eeg) changes of women with and without history of chemotherapy exposure undergoing volatile general anesthesia. secondary objective: i. to evaluate if chemotherapy-induced cognitive impairment is associated with an increased sensitivity to general anesthetic agents captured by the patient state index (psi) and observable in changes in alpha (8-12 h) activity in the frontal regions of the eeg) and other study features such as eeg power, burst suppression analysis, burst suppression ratio, and coherence analysis. exploratory objectives: i. to assess the relationship between preoperative cognitive function and electroencephalographic changes under general anesthesia. ii. to assess the relationship between eeg signatures under general anesthesia and postoperative cognitive function. iii. to collect blood specimens for extracting information on serum lipids and cytokines at two different times, before anesthetic induction, and 30 to 60 minutes upon arrival to the postoperative anesthesia care unit. outline: patients undergo cognitive function assessment braincheck over 10 minutes before surgery, day 1 after surgery, and day 2 after surgery (if patients are still admitted to the hospital) and 3d-confusion assessment over 10 minutes twice daily (bid) on day 1 after surgery and day 2 after surgery (if patients are still admitted to the hospital). patients also undergo eeg during surgery and collection of blood samples 30-60 minutes after surgery.

Eligibility criteria:
inclusion criteria: 1. written informed consent; 2. women between 40-60 years of age; with or without history of systemic chemotherapy; 3. american society of anesthesiologists physical status (asa) 1-3; 4. scheduled surgery: open gynecologic surgery; 5. able to complete all study questionnaires. exclusion criteria: 1. emergency surgery 2. asa ≥ 4 3. patients with extra-abdominal metastatic disease 4. patients unable to complete preoperative and postoperative cognitive tests 5. non-english-speaking patients
bioinductive patch for full-thickness rotator cuff tears

Conditions: Rotator Cuff Tears; Rotator Cuff Tear Arthropathy

Summary: the purpose of this randomized-controlled study is to compare outcomes of arthroscopic rotator cuff repair augmented with a bioinductive implant (study group) to standard arthroscopic rotator cuff repair (control group). the primary outcome of this study is rotator cuff repair integrity (absence of full- or partial-thickness defect) demonstrated on ultrasound at 1-year postoperatively. the investigators hypothesize that the study group will have higher rates of repair integrity demonstrated on ultrasound at 1-year postoperatively.

a bioinductive patch is an implant that may foster tendon regrowth and healing following surgery. patients will be randomized into one of two groups: control and investigational. all surgical patients will have failed non-surgical/conservative options for 6 weeks. patients in the "control group" will receive the standard surgery (arthroscopic rotator cuff repair) . patients in the "experimental group" will receive the same surgical treatment, with the addition of the bioinductive patch. this patch will be implanted during surgery. then, using a combination of ultrasound studies and other measures, the investigators will assess how well the patch works compared to surgery alone.

Eligibility criteria:
inclusion criteria: * indicated and scheduled for arthroscopic rotator cuff repair. * full-thickness medium (1-3 cm), large (3-5 cm), and massive (\>5 cm) rotator cuff tears involving the supraspinatus and/or infraspinatus tendons demonstrated on magnetic resonance or ultrasound imaging. * chronic, degenerative rotator cuff tears. * ability to read and understand english. * age ≥18 years * patient failed ≥6 weeks of conservative treatment, which included structured, in-person physical therapy or documented home therapy exclusion criteria: * patient scheduled for open or mini-open rotator cuff repair * prior surgery of affected shoulder (except diagnostic arthroscopy) * partial-thickness rotator cuff tears * small (\<1 cm) rotator cuff tears * rotator cuff tears involving the subscapularis tendon * acute and traumatic rotator cuff tears * active infection * cancer * autoimmune and rheumatologic disorders, including rheumatoid arthritis, psoriatic arthritis, systemic lupus erythematosus

Keywords: rotator cuff tear bioinductive arthroscopic rotator cuff repair rotator cuff tear arthropathy
research report: ceriter clinical study - stride one

Conditions: CVA (Cerebrovascular Accident)

Summary: the goal of this clinical study is to investigate the short-term impact of the use of ceriter stride one on the quality of gait in patients rehabilitating after a cerebrovascular accident (cva). stride one is a smart insole that provides real-time audio feedback (cues) to the patient when performing a certain exercise. the main questions it aims to answer are: * will patients with a cva show a qualitatively better gait pattern after training with a stride one insole? * can patients maintain this improvement in gait pattern without audio feedback at the end of the training? participants will * receive daily gait rehabilitation using stride one for 1 week * the quality of the gait pattern was evaluated at the beginning and at the end of the week, with and without the use of stride one * an additional evaluation was performed three to four days after the end of therapy without the use of stride one * immediately after the end of the intervention week, the patient and the treating therapist were asked about their findings regarding the use of stride one while walking

both therapist and patient reported an improvement in the quality of the foot roll-off pattern in 100% of cases. this improvement was also objectively determined in the data measured by stride one, with an average of 8% improvement on stride one general quality parameter, and an average of 25% improvement on stride one specific quality parameter for the specific patient. furthermore, 89% of patients indicate that using stride one helps them to understand their physiotherapist better, and 67% of patients indicate that they can practice more and better with stride one. practicing one week with stride one generates a positive clinical impact on the gait pattern. a lasting improvement in the gait pattern without using stride one, three to four days after the intervention, could not be demonstrated in this short time period. further research is needed to evaluate the effect of stride one after more long-term use. additional research questions are suggested.

Eligibility criteria:
inclusion criteria: * cva, residentially admitted to the rehabilitation center in herk-de-stad, belgium * older than 18 years of age * gait problems as a result of the cva * able to walk safely and independently (possibly with a walking aid) * able to understand and sign an information and consent form exclusion criteria: * severe cognitive problems (attention) that make it difficult to understand instructions or follow feedback * hearing problem

Keywords: cva (cerebrovascular accident) gait rehabilitation gait analysis tele-rehabilitation
phase i folfox combination

Conditions: Advanced Colorectal Carcinoma

Summary: a phase i,open label study to assess the safety and tolerability of zd6474 in combination with 5-fluorouracil, leucovorin and oxaliplatin (mfolfox6) as first and second line therapy in patients with advanced colorectal adenocarcinoma.


Eligibility criteria:
inclusion criteria: 1. histologically confirmed locally advanced, recurrent or metastatic colorectal adenocarcinoma (stage iv) 2. who performance status 0-1 3. one or more measurable lesions min 10mm by spiral ct or min 20mm by conventional techniques exclusion criteria: 1. brain metastasis or spinal cord compression unless irradiated at least 4 weeks before entry and stable 2. last dose of prior chemotherapy discontinued at least 4 weeks before start study treatment 3. prior unanticipated severe reaction to oxaliplatin

Keywords: zd6474 folfox colorectal adenocarcinoma
comparison of the efficacy of fractional er:yag laser for acne scar

Conditions: Scar

Summary: compare the efficacy of frational er:yag laser and that of bipolar frequency with diode laser treatment.

in acne scar treatment, ablational laser would be superior to nonablative laser treatment. frational er:yag laser treatment is a effective treatment plan for acne scar without severe adverse effects.

Eligibility criteria:
inclusion criteria: * moderate acne scar exclusion criteria: * taking steroids, nonsteroidal antiinflammatory drug, and isotretinoin * anyone who received acne scar procedures within 6 months * underlying diabetes mellitus, keloid, or malignancy

Keywords: acne scar laser therapy wound healing
efficacy and safety of tozorakimab in patients hospitalised for viral lung infection requiring supplemental oxygen

Conditions: Viral Lung Infection and Acute Respiratory Failure

Summary: the purpose of this study is to evaluate the effect of tozorakimab, as an add-on to soc in patients with viral lung infection requiring supplemental oxygen, on the prevention of death or progression to imv/ecmo.


Eligibility criteria:
inclusion criteria: * adult participants ≥ 18 years old at the time of signing the informed consent form. * patients hospitalised with viral lung infection. * hypoxaemia requiring treatment with supplemental o2. hypoxaemia is defined as: spo2 ≤ 90% or spo2 ≤ 92% and one or both of the following: radiographic infiltrates by cxr/ct compatible with viral lung infection per investigator judgement. use of accessory muscles of respiration or rr (respiratory rate) \> 22. - patient remains hypoxaemic at randomisation requiring treatment with supplemental oxygen. exclusion criteria: * known fungal or parasitic lung infection, aspiration lung infection, lung abscess, or evidence of septic shock. bacterial co-infection is allowed, unless, in the opinion of the investigator, bacterial infection defines the severity of the participant's condition. * hypoxaemia caused primarily by extrapulmonary insult or by lung injury of non-infective aetiology. * ongoing imv/ecmo at randomisation.

Keywords: acute respiratory failure acute respiratory distress syndrome viral lung infection tozorakimab supplemental oxygen il-33 covid-19 sars-cov-2 coronavirus infections virus diseases sars coronavirus medi3506 respiratory tract infections infections lung diseases influenza
safety and dosage study of rad001 (everolimus) in combination with current standard of care to treat advanced solid tumors.

Conditions: Unspecified Adult Solid Tumor, Protocol Specific; Cancer

Summary: the purpose of this study is to determine if rad001 (everolimus) helps improve the standard treatment of xelox-a (bevacizumab, oxaliplatin, capecitabine) in advanced solid tumors.


Eligibility criteria:
inclusion criteria: * must be 18 years or older * must have a performance status of at least 70% (able to carry on most normal activities) * must have life expectancy of at least 3 months * must have adequate organ and marrow function as determined by lab tests * women of child-bearing potential and men must agree to use two forms of contraception * ability and willingness to sign a written informed consent document * histologically confirmed solid tumor malignancy that is metastatic or unresectable exclusion criteria: * pregnant or breastfeeding and/or lactating women * patients who have received any other investigational agents within 28 days of the first day of study drug * patients with known cns metastases * history of other carcinomas within last 5 years (except non-melanoma skin cancer, in-situ cervical cancer, localized prostate cancer) * inadequately controlled hypertension * significant vascular disease * invasion or encasement of a major artery * evidence of bleeding diathesis or coagulopathy * major surgical procedure, open biopsy or significant traumatic injury within 28 days prior to day 1 of study drug * serious illness or medical condition * history of myocardial infarction, unstable angina, cardiac or other vascular stenting * history of stroke * hiv, hepatitis c, hepatitis b or other serious chronic infection * impairment of gastrointestinal function or disease * history of interstitial lung disease * patients who have had radiation therapy, hormonal therapy, biologic therapy or chemotherapy for cancer within 28 days of receiving study drug.

Keywords: advanced solid tumors cancer capecitabine xelox neoplasms oxaliplatin bevacizumab rad001
telephone-based re-education for hp eradication

Conditions: Helicobacter Pylori Infection

Summary: it was suggested that the patient compliance plans an important role in the hp eradication. however, data on whether re-education could improve the eradication rate are lacking. we consider that re-education on patients by telephone during the process of drug administration could increase the eradication rate in hp infected patients. we hypothesized that telephone re-education during the whole process of drug administration would improve the compliance of patients and ultimately increase the hp eradication rate.


Eligibility criteria:
inclusion criteria: 1. prior informed consent 2. 18-70 years of age 3. hp infected patients diagnosed by 13c urea breath test, including digestive ulcer, gastritis with dyspepsia symptoms, family history of gastric cancer, planning to use long-term non-steroidal anti-inflammatory drugs (nsaids), or personal request 4. ability to swallow oral medications 5. no contraindication for the drugs used for hp eradication 6. both men and women enrolled in this trial must use adequate barrier birth control during the course of the trial and 4 weeks after the completion of trial exclusion criteria: 1. pregnant or breast-feeding subjects 2. previous failed treatment of hp eradication 3. previous treatment with bismuth salts or antibiotics within 1 month before study enrollment, and treatment with proton pump inhibitor or h2 receptor antagonist within 2 weeks before study enrollment 4. any disease that could jeopardize the safety of subject and their compliance in the study (e.g. serious liver disease, heart disease, kidney disease, malignant tumor or alcoholism, etc.) 5. previous upper gastrointestinal surgery 6. inability to express complaint (e.g. mental disorder, psychoneurosis, unable to cooperation, etc.) 7. active clinically serious infections, except for hepatitis b virus and hepatitis c virus infection 8. clinically significant gastrointestinal bleeding within 4 weeks prior to start of study drug

Keywords: helicobactor pylori
efficacy and safety of diclofenac ddea 2.32 % in patient suffering from knee osteoarthritis (oa)

Conditions: Osteoarthritis, Knee

Summary: this study will evaluate the efficacy and safety of diclofenac ddea 2.32 % in patient suffering from knee osteoarthritis (oa).


Eligibility criteria:
inclusion criteria: * 1. male or female ≥ 50 years old; 2. symptomatic oa of one or both knees, according to acr criteria, diagnosed at least 6 months previously; 3. pain in either knee originates in the knee (not referred pain from other sites, such as hip or back) and no other cause of pain than knee oa; 4. have used oral nsaids or coxibs for the knee oa pain (including aspirin if ≥ 500 mg and used in this indication), at least one dose per day, for not less than 10 days out of the 14 days preceding the screening visit and also within the 24 hours preceding the screening visit; 5. be able to tolerate rescue medication with only 500 mg paracetamol (apap) taken in doses of 1-2 tablets up to a maximum of 6 tablets (3 grams) per day for the duration of the study exclusion criteria: - 1. partial or total replacement of either knee joint, past or planned/expected during study duration. 2. oa of the knee due to other underlying conditions, such as gout, chondrocalcinosis, hemochromatosis, joint infections, neuropathia, or severe traumatic joint damage (however, common risk factors, such as obesity and past meniscectomy or ligament rupture and repair, are allowed); 3. history of systemic inflammatory (autoimmune) disease (rheumatoid arthritis, systemic psoriasis, systemic lupus erythematosus, systemic sclerosis, etc.) or laboratory values indicative of such disease with subsequent diagnosis by a physician; 4. fibromyalgia within the previous year; 5. allergy or asthma to diclofenac, apap, aspirin, other nsaids or any of the ingredients in the gel (i.e. isopropyl alcohol, propylene glycol, or butylhydroxytoluene), or any other contraindication for the study drug or the rescue medication

Keywords: symptomatic knee oa kellgren-lawrence grade 1-3
closed-loop insulin delivery systems in pancreatic diabetes

Conditions: Secondary Pancreatic Diabetes

Summary: the purpose of this study is to evaluate the metabolic and the safety outcomes in people living with pancreatic diabetes (pancreatitis or pancreatectomy-induced diabetes) and using a closed-loop insulin delivery systems ("artificial pancreas").

secondary pancreatic diabetes is an unstable diabetes, due to deficiency in b cells which produce insulin, alpha cells which produce glucagon, and exorcrine insufficiency. patients with secondary pancreatic diabetes are exposed to high glycemic variability and severe hypoglycemic episodes. hybrid closed loop treatment has shown efficacy and safety for patients with type 1 diabetes and has the potential to improve the control of secondary pancreatic diabetes but has rarely been studied in this particular indication. a retrospective observational cohort study in patients will be contucted suffering from secondary pancreatic diabetes in whom this device was implemented in order to observe metabolic and safety outcomes compared to the period before they were treated with hybrid closed-loop system.

Eligibility criteria:
inclusion criteria: * adult patient * presenting secondary pancreatic diabetes * treatment with insulin closed-loop delivery exclusion criteria: * patient who objected to the use of data

Keywords: closed-loop insulin delivery systems artificial pancreas pancreatitis pancreatectomy secondary diabetes continuous glucose monitoring
waxing and waning of serum sars cov-2-igg level in covid-19 exposed population

Conditions: Covid19

Summary: this study will define the kinetics of igg responses to both n and s proteins in the subjects who suffered from covid 19 and then had recovered and those who were previously undiagnosed but were seropositive. these subjects will be followed for four months to evaluate the levels of antibodies in these people.

since december 2019, cases of unexplained pneumonia have occurred in wuhan city, hubei province, subsequent virus isolation and whole-genome sequencing (accession#: mn908947) confirmed that it is an acute respiratory infection caused by new severe acute respiratory syndrome coronavirus 2 (sars-cov-2) . coronaviruses are enveloped, non-segmented, single-positive-stranded rna viruses with round or oval particles and a diameter of 50-200 nm. coronavirus subfamily is divided into four genera: α, β, γ and δ according to serotype and genomic characteristics. the sars-cov-2 belongs to the genus β which has been confirmed to be highly infectious by research. the four major structural proteins of coronavirus are the spike surface glycoprotein (s), small envelope protein (e), matrix protein (m), and nucleocapsid protein (n). the spike protein (s) of coronavirus is a type i transmembrane glycoprotein and mediates the entrance to human respiratory epithelial cells by interacting with cell surface receptor angiotensin-converting enzyme 2 (ace2), the s protein contains distinct functional domains near the amino (s1) and carboxy (s2) termini, the peripheral s1 portion can independently bind cellular receptors while the integral membrane s2 portion is required to mediate fusion of viral and cellular membranes . the nucleocapsid protein (n) forms complexes with genomic rna, interacts with the viral membrane protein during virion assembly and plays a critical role in enhancing the efficiency of virus transcription and assembly the seropositivity rate of both igm and igg responses after onset and recovery of disease, and in the context of both n protein and s protein has not been clarified. the kinetics of antibody responses in critical cases or icu patients has not been reported, and no studies have suggested whether antibody response is associated with disease prognosis

Eligibility criteria:
inclusion criteria: * subjects testing reactive for sars cov 2 igg antibodies exclusion criteria: * subjects testing nonreactive for sars cov-2 igg antibodies
safety and efficacy study of bimatoprost in the treatment of women with female pattern hair loss

Conditions: Alopecia; Baldness

Summary: this study will evaluate the safety and efficacy of 3 doses of bimatoprost solution compared with vehicle and over-the-counter (otc) minoxidil 2% solution in women with female pattern hair loss. all treatments will be provided in a double-blinded fashion except for minoxidil 2% solution which will be provided open-label.


Eligibility criteria:
inclusion criteria: * mild to moderate female pattern hair loss with ongoing hair loss for at least 1 year * willingness to have micro-dot-tattoo applied to scalp * willingness to maintain same hair style, length and hair color during study exclusion criteria: * drug or alcohol abuse within 12 months * hiv positive * received hair transplants or had scalp reductions * use of hair weaves, hair extensions or wigs within 3 months * oral or topical minoxidil treatment within 6 months * application of topical steroids or nonsteroidal anti-inflammatory drugs (nsaids) to scalp within 4 weeks
prophylactic intravesical chemotherapy to prevent bladder tumors after nephroureterectomy for primary upper urinary tract urothelial carcinomas

Conditions: Upper Tract Urothelial Carcinoma; Bladder Recurrence

Summary: the purpose of this study is to evaluate the efficacy of prophylactic intravesical chemotherapy (different chemotherapy drugs and dosage regimen) in the prevention of bladder recurrence after nephroureterectomy for upper tract urothelial carcinoma (utuc).


Eligibility criteria:
inclusion criteria: 1. patients who were clinically diagnosed with utuc 2. treated with radical nephroureterectomy exclusion criteria: 1. distant metastasis 2. prior history of bladder or synchronous bladder cancer 3. administration of neoadjuvant chemotherapy 4. presence of severe complications.